Beverly Hills Private Wealth LLC Buys Shares of 7,459 QIAGEN N.V. (NYSE:QGEN)

Beverly Hills Private Wealth LLC acquired a new stake in shares of QIAGEN N.V. (NYSE:QGEN - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 7,459 shares of the company's stock, valued at approximately $299,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Brown Brothers Harriman & Co. bought a new stake in QIAGEN in the fourth quarter valued at $37,000. EverSource Wealth Advisors LLC grew its position in QIAGEN by 152.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock valued at $39,000 after acquiring an additional 526 shares during the period. Smartleaf Asset Management LLC grew its position in QIAGEN by 148.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after acquiring an additional 835 shares during the period. Tower Research Capital LLC TRC grew its position in QIAGEN by 770.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after acquiring an additional 2,204 shares during the period. Finally, GAMMA Investing LLC grew its position in QIAGEN by 93.9% in the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after acquiring an additional 1,425 shares during the period. 70.00% of the stock is currently owned by institutional investors.

QIAGEN Trading Down 0.9%

Shares of QGEN traded down $0.42 during trading hours on Friday, hitting $48.13. 2,421,661 shares of the stock traded hands, compared to its average volume of 1,214,196. The company has a current ratio of 3.37, a quick ratio of 2.83 and a debt-to-equity ratio of 0.40. QIAGEN N.V. has a 1-year low of $37.63 and a 1-year high of $49.30. The firm has a market capitalization of $10.70 billion, a PE ratio of 120.67, a price-to-earnings-growth ratio of 2.47 and a beta of 0.68. The business has a fifty day moving average of $45.37 and a 200-day moving average of $42.83.

QIAGEN (NYSE:QGEN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.05. QIAGEN had a return on equity of 14.61% and a net margin of 4.68%. The business had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. During the same quarter in the prior year, the firm posted $0.44 earnings per share. The firm's revenue for the quarter was up 5.2% compared to the same quarter last year. Analysts expect that QIAGEN N.V. will post 2.26 EPS for the current year.

QIAGEN Dividend Announcement

The business also recently announced a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were paid a $0.25 dividend. This represents a yield of 0.52%. The ex-dividend date was Wednesday, July 2nd. QIAGEN's payout ratio is 62.50%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on QGEN shares. Wall Street Zen raised QIAGEN from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Redburn Atlantic lowered QIAGEN from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Bank of America boosted their price objective on QIAGEN from $50.00 to $53.00 and gave the stock a "buy" rating in a research note on Thursday, June 26th. Robert W. Baird boosted their price objective on QIAGEN from $42.00 to $43.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Finally, Barclays started coverage on QIAGEN in a research note on Tuesday, June 24th. They issued an "overweight" rating and a $55.00 price objective on the stock. Seven investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $49.40.

About QIAGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.